SEARCH

SEARCH BY CITATION

References

  • 1
    Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410 15.
  • 2
    Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313 19.
  • 3
    Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis at diagnosis. Gastroenterology 1994; 107: 1031 9.
  • 4
    Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543 6.
  • 5
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterology 1989; 24 (sp170), 2 15.
  • 6
    Harvey RF & Bradshaw JM. A simple index of Crohn’s disease activity. Lancet 1980; March 8: 514514.
  • 7
    Francis RM, Peacock M, Aaron JE, et al. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium metabolism and low bone formation. Bone 1986; 7: 261 8.
  • 8
    Jackson JA, Kleerekoper M, Parfitt AM, Rao DS, Villaneuva AR, Frame B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53 8.
  • 9
    Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing 1992; 21: 139 41.
  • 10
    Stanley HL, Brian PS, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991; 39: 766 71.
  • 11
    Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long term treatment with glucocorticoids in human subjects. J Clin Endocrinol Metab 1975; 104: 648 51.
  • 12
    Vermeulen A, Verdonck L, Van der Straeten M, Orie N. Capacity of the testosterone-binding globulin in human plasma and influence of specific binding of testosterone on its metabolic clearance rate. J Clin Endocrinol 1969; 29: 1470 80.
  • 13
    Goussis OS, Pardridge WM, Judd HL. Critical illness and low testosterone: Effects of human serum on testosterone transport into rat brain and liver. J Clin Endocrinol Metab 1983; 56(4): 710 14.
  • 14
    Gordon D, Beastall GH, Thomson JA, Sturrock RD. Androgenic status and sexual function in males with rheumatoid arthritis and ankylosing spondilitis. Q J Med 1986; 231: 671 9.
  • 15
    Delmas PD, Malaval L, Arlot MD, Meunier PJ. Serum bone Gla-protein compared to bone histomorphometry in endocrine diseases. Bone 1985; 6: 329 41.
  • 16
    Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporosis Int 1993; 3(5): 236 41.
  • 17
    Abitol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417 22.
  • 18
    Young NR, Baker HW, Liu G, Seeman E. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception. J Clin Endocrinol Metab 1993; 77(4): 1028 32.
  • 19
    Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis—effects of 6 months treatment on bone mineral density and cardiovascular risk factors. Bone 1996; 18(2): 171 7.